Patents by Inventor Zhengping Zhuang

Zhengping Zhuang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11351185
    Abstract: A pharmaceutical composition containing any one or more of 4?-O-isolvalerylspiramycin I, II and III counters tumorigenesis and reduces or prevents metastasis by inhibiting selenoprotein H to trigger genomic instability and cell-cycle arrest in cancer cells.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: June 7, 2022
    Assignees: ASCLEA CORPORATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH
    Inventors: Enhong Jiang, Zhengping Zhuang, Jing Cui
  • Publication number: 20220009980
    Abstract: Methods of decreasing cell viability of cancer cells, increasing apoptosis of cancer cells, and treating cancer in a mammal with cancer are provided. The methods include administering (i) a polypeptide comprising an amino acid sequence with at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1, (ii) a nucleic acid molecule comprising a nucleic acid sequence encoding the polypeptide, (iii) a vector comprising the nucleic acid molecule, (iv) a recombinant cell comprising any one of (i)-(iii), and/or (v) a composition comprising any one of (i)-(iv).
    Type: Application
    Filed: November 13, 2019
    Publication date: January 13, 2022
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Zhengping Zhuang, Emeline Tabouret, Herui Wang, Harish Pant, Niranjana D. Amin
  • Publication number: 20210346430
    Abstract: Disclosed is a method for treating glioblastoma or other brain tumors. The method includes steps of preparing cells comprising a chimeric antigen receptor (CAR) molecule and administering to a mammal in need thereof an effective amount of the prepared cells. Also disclosed is that the CAR molecule contains an antigen binding domain that binds to the tumor antigen associated with the glioblastoma or other brain tumors, and the tumor antigen is carbonic anhydrase IX.
    Type: Application
    Filed: August 23, 2019
    Publication date: November 11, 2021
    Inventors: Zhengping Zhuang, Kaiyong Yang, Jing Cui, Qi Zhang
  • Publication number: 20210283159
    Abstract: A pharmaceutical composition containing any one or more of 4?-O-isolvalerylspiramycin I, II and III counters tumorigenesis and reduces or prevents metastasis by inhibiting selenoprotein H to trigger genomic instability and cell-cycle arrest in cancer cells.
    Type: Application
    Filed: March 11, 2020
    Publication date: September 16, 2021
    Applicants: ASCLEA CORPORATION, THE UNITED STATES OF AMERICA, as represented by the Secretary, Dept, of Health and Human Svcs.
    Inventors: Enhong JIANG, Zhengping ZHUANG, Jing CUI
  • Publication number: 20210052644
    Abstract: Disclosed is a method for treating glioblastoma or other brain tumors. The method includes steps of preparing cells comprising a chimeric antigen receptor (CAR) molecule and administering to a mammal in need thereof an effective amount of the prepared cells. Also disclosed is that the CAR molecule contains an antigen binding domain that binds to the tumor antigen associated with the glioblastoma or other brain tumors, and the tumor antigen is carbonic anhydrase IX.
    Type: Application
    Filed: August 23, 2019
    Publication date: February 25, 2021
    Inventors: Zhengping Zhuang, Kaiyong Yang, Jing Cui, Qi Zhang
  • Publication number: 20200069680
    Abstract: The present invention provides a method of treating a subject afflicted with cancer comprising administering to the subject an effective amount of a PP2A inhibitor.
    Type: Application
    Filed: December 8, 2017
    Publication date: March 5, 2020
    Inventors: John S. Kovach, Zhengping Zhuang, Sze Chun Winson Ho, Herui Wang, Rongze Lu
  • Publication number: 20170136008
    Abstract: A method of treating ovarian cancer in a subject afflicted therewith comprising administering to the subject an effective amount of an anti-cancer agent and an effective amount of a compound having the structure:
    Type: Application
    Filed: June 19, 2015
    Publication date: May 18, 2017
    Applicants: Lixte Biotechnology, Inc., The United States of America, as Represented by th e Secretary, Department of Health & Human Service
    Inventors: John S. Kovach, Zhengping Zhuang, Ki-eun Chang, Matthew Hall, Michael M. Gottesman
  • Publication number: 20140235649
    Abstract: A method of treating a mammalian subject afflicted with a disease characterized by a loss of protein function caused by a genetic abnormality associated with the disease comprising administering to the subject a therapeutically effective amount of a protein phosphatase 2A inhibitor or a histone deacetylase inhibitor.
    Type: Application
    Filed: May 24, 2012
    Publication date: August 21, 2014
    Applicant: LIXTE BIOTECHNOLOGY, INC.
    Inventors: John S. Kovach, Zhengping Zhuang, Jie Lu, Chunzhang Yang, Russell Lonser
  • Publication number: 20100029683
    Abstract: Disclosed herein are methods of inhibiting proliferation of a cancer cell or inducing apoptosis of a cancer cell, which does not overexpress N—CoR. Also disclosed herein are methods of inhibiting proliferation or inducing apoptosis of a cancer cell that overexpresses TCTP and methods for determining whether a compound is effective in inducing cell death.
    Type: Application
    Filed: July 17, 2009
    Publication date: February 4, 2010
    Inventors: John S. Kovach, Zhengping Zhuang, Jie Lu
  • Publication number: 20090035292
    Abstract: Disclosed herein are methods of treating neuroblastomas and medulloblastomas in a subject comprising administering to the subject a phosphatase ligand in an amount effective to treat the subject. Also disclosed herein are method of treating neuroblastomas and medulloblastomas in a subject comprising administering to the subject a histone deacteylase ligand in an amount effective to treat the subject.
    Type: Application
    Filed: August 1, 2008
    Publication date: February 5, 2009
    Inventors: John S. Kovach, Zhengping Zhuang
  • Publication number: 20090018142
    Abstract: This invention provides a method of treating a patient suffering from a tumor overexpressing N—CoR comprising administering to the patient a phosphatase ligand, alone or in combination with a retinoid receptor ligand, a histone deacetylase ligand, or both, in amounts effective to treat the patient. This invention also provides a method of inhibiting tumor growth in a patient suffering from a tumor overexpressing N—CoR. This invention further provides a method of identifying a compound or a mixture of compounds capable of inducing differentiation of cells of a tumor overexpressing N—CoR. This invention still further provides a method of determining the likelihood of successfully treating a subject suffering from a tumor overexpressing N—CoR. This invention also provides a method of assessing the likelihood that a patient is suffering from a tumor overexpressing N—CoR.
    Type: Application
    Filed: February 6, 2007
    Publication date: January 15, 2009
    Inventors: Zhengping Zhuang, Edward H. Oldfield, Deric M. Park, Irina Lubensky, Jie Li, John S. Kovach
  • Publication number: 20080214569
    Abstract: This invention provides a method of treating a patient suffering from a tumor overexpressing N—CoR comprising administering to the patient a phosphatase ligand, alone or in combination with a retinoid receptor ligand, a histone deacetylase ligand, or both, in amounts effective to treat the patient. This invention also provides a method of inhibiting tumor growth in a patient suffering from a tumor overexpressing N—CoR. This invention further provides a method of identifying a compound or a mixture of compounds capable of inducing differentiation of cells of a tumor overexpressing N—CoR. This invention still further provides a method of determining the likelihood of successfully treating a subject suffering from a tumor overexpressing N—CoR. This invention also provides a method of assessing the likelihood that a patient is suffering from a tumor overexpressing N—CoR.
    Type: Application
    Filed: February 8, 2007
    Publication date: September 4, 2008
    Inventors: Zhengping Zhuang, Edward H. Oldfield, Deric M. Park, Irina Lubensky, Jie Li, John S. Kovach
  • Patent number: 7358347
    Abstract: The invention relates to the discovery of a novel tumor suppressor gene which is associated with multiple endocrine neoplasia type 1. The gene has been designated MEN1 and the gene product is menin. The absence of this protein and associated mutations in the corresponding gene have been identified in individuals suffering from multiple endocrine neoplasia type 1. The identification of this marker for multiple endocrine neoplasia type 1 has diagnostic uses as well as for gene therapy.
    Type: Grant
    Filed: March 4, 1998
    Date of Patent: April 15, 2008
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Settara Chandrasekharappa, Siradanahalli Guru, Pachiappan Manickam, Francis S. Collins, Michael R. Emmert-Buck, Larisa V. Debelenko, Irina A. Lubensky, Lance A. Liotta, Sunita K. Agarwal, Allen M. Spiegel, A. Lee Burns, Stephen J. Marx, Zhengping Zhuang
  • Patent number: 6569639
    Abstract: A method of microdissection which involves: forming an image field of cells of the tissue sample utilizing a microscope, identifying at least one zone of cells of interest from the image field of cells which at least one zone of cells of interest includes different types of cells than adjacent zones of cells, and extracting the at least one zone of cells of interest from the tissue sample. The extraction is achieved by contacting the tissue sample with a transfer surface that can be selectively activated so that regions thereof adhere to the zone of cells of interest to be extracted. The transfer surface includes an activatable adhesive layer which provides chemical or electrostatic adherence to the selected regions of the tissue sample. After the transfer surface is activated the transfer surface and tissue sample are separated. During separation the zone of cells of interest remains adhered to the transfer surface and is thus separated from the tissue sample.
    Type: Grant
    Filed: January 18, 2001
    Date of Patent: May 27, 2003
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Lance A. Liotta, Michael E. Buck, Rhonda Ann Weiss, Zhengping Zhuang, Robert F. Bonner
  • Publication number: 20010031481
    Abstract: A method of microdissection which involves: forming an image field of cells of the tissue sample utilizing a microscope, identifying at least one zone of cells of interest from the image field of cells which at least one zone of cells of interest includes different types of cells than adjacent zones of cells, and extracting the at least one zone of cells of interest from the tissue sample. The extraction is achieved by contacting the tissue sample with a transfer surface that can be selectively activated so that regions thereof adhere to the zone of cells of interest to be extracted. The transfer surface includes an activatable adhesive layer which provides chemical or electrostatic adherence to the selected regions of the tissue sample. After the transfer surface is activated the transfer surface and tissue sample are separated. During separation the zone of cells of interest remains adhered to the transfer surface and is thus separated from the tissue sample.
    Type: Application
    Filed: January 18, 2001
    Publication date: October 18, 2001
    Inventors: Lance A. Liotta, Michael E. Buck, Rhonda Ann Weiss, Zhengping Zhuang, Robert F. Bonner
  • Patent number: 6204030
    Abstract: A method of microdissection which involves: forming an image field of cells of the tissue sample utilizing a microscope, identifying at least one zone of cells of interest from the image field of cells which at least one zone of cells of interest includes different types of cells than adjacent zones of cells, and extracting the at least one zone of cells of interest from the tissue sample. The extraction is achieved by contacting the tissue sample with a transfer surface that can be selectively activated so that regions thereof adhere to the zone of cells of interest to be extracted. The transfer surface includes an activatable adhesive layer which provides chemical or electrostatic adherence to the selected regions of the tissue sample. After the transfer surface is activated the transfer surface and tissue sample are separated. During separation the zone of cells of interest remains adhered to the transfer surface and is thus separated from the tissue sample.
    Type: Grant
    Filed: September 2, 1999
    Date of Patent: March 20, 2001
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Lance A. Liotta, Michael E. Buck, Rhonda Ann Weiss, Zhengping Zhuang, Robert F. Bonner
  • Patent number: 6010888
    Abstract: A method of microdissection which involves: forming an image field of cells of the tissue sample utilizing a microscope, identifying at least one zone of cells of interest from the image field of cells which at least one zone of cells of interest includes different types of cells than adjacent zones of cells, and extracting the at least one zone of cells of interest from the tissue sample. The extraction is achieved by contacting the tissue sample with a transfer surface that can be selectively activated so that regions thereof adhere to the zone of cells of interest to be extracted. The transfer surface includes an activatable adhesive layer which provides chemical or electrostatic adherence to the selected regions of the tissue sample. After the transfer surface is activated the transfer surface and tissue sample are separated. During separation the zone of cells of interest remains adhered to the transfer surface and is thus separated from the tissue sample.
    Type: Grant
    Filed: September 8, 1997
    Date of Patent: January 4, 2000
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Lance A. Liotta, Michael E. Buck, Rhonda Ann Weiss, Zhengping Zhuang, Robert F. Bonner
  • Patent number: 5843644
    Abstract: A method of direct extraction of cellular material from a tissue sample which involves: forming an image field of cells of the tissue sample utilizing a microscope, identifying at least one zone of cells of interest from the image field of cells which at least one zone of cells of interest includes different types of cells than adjacent zones of cells, and extracting the at least one zone of cells of interest from the tissue sample. The extracted zone(s) of cells is subjected to analysis. The overall process of identifying, extracting, transporting, and analyzing the extracted zones(s) of cells can be fully automated.
    Type: Grant
    Filed: March 1, 1994
    Date of Patent: December 1, 1998
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Lance A. Liotta, Zhengping Zhuang, Michael R. Buck, William G. Stetler-Stevenson, Irina A. Lubensky, Mark J. Roth